Provided by Tiger Trade Technology Pte. Ltd.

Ovid Therapeutics Inc.

1.45
-0.0200-1.36%
Volume:427.82K
Turnover:626.20K
Market Cap:188.77M
PE:-2.87
High:1.49
Open:1.45
Low:1.44
Close:1.47
52wk High:2.01
52wk Low:0.2425
Shares:130.18M
Float Shares:59.52M
Volume Ratio:0.64
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5047
EPS(LYR):-0.3663
ROE:-60.06%
ROA:-29.33%
PB:4.22
PE(LYR):-3.96

Loading ...

Ovid Therapeutics Inc - Meg Alexander Appointed CEO Effective January 1, 2026

THOMSON REUTERS
·
Nov 12, 2025

Press Release: Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Dow Jones
·
Nov 12, 2025

Ovid Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Ovid Therapeutics Inc. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Oct 28, 2025

Oppenheimer upgrades Ovid Therapeutics (OVID) to a Buy

TIPRANKS
·
Oct 09, 2025

William Blair Sticks to Its Buy Rating for Ovid Therapeutics (OVID)

TIPRANKS
·
Oct 04, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Occidental Petroleum , GameStop, Alphabet

Reuters
·
Oct 03, 2025

Exchange-Traded Funds, Equity Futures Higher Pre-Bell as Investors Eye Another Interest Rate Cut for 2025

MT Newswires Live
·
Oct 03, 2025

Ovid Therapeutics Agrees to Financing Deal Worth up to $175 million

MT Newswires Live
·
Oct 03, 2025

BUZZ-Ovid Therapeutics jumps after seizure treatment shows promise in trial

Reuters
·
Oct 03, 2025

Ovid Shares Leap Premarket on Positive Study Results, Financing Pact

Dow Jones
·
Oct 03, 2025

Top Premarket Gainers

MT Newswires Live
·
Oct 03, 2025

Ovid Therapeutics Shares up 25.6% Premarket After Co Reports Early-Stage Data for Seizure Treatment

THOMSON REUTERS
·
Oct 03, 2025

Ovid Therapeutics prices private placement up to $175M in gross proceeds

TIPRANKS
·
Oct 03, 2025

Ovid Therapeutics Announces $175 Million Private Placement to Fund Pipeline Through 2028

Reuters
·
Oct 03, 2025

Ovid Therapeutics Announces Positive Phase 1 Results for OV329, Plans Phase 2a Trial for Drug-Resistant Focal Onset Seizures in 2026

Reuters
·
Oct 03, 2025

Ovid Therapeutics Inc - Ov329 Safety Results Preferable to Marketed Asms

THOMSON REUTERS
·
Oct 03, 2025

Ovid Therapeutics Inc - Ov329 Matched or Exceeded Vigabatrin Inhibition on Tms

THOMSON REUTERS
·
Oct 03, 2025

Ovid Announces Positive Topline Results for the Next-Generation Gaba-Aminotransferase Inhibitor, Ov329, That Demonstrate Strong Inhibitory Activity and a Potential Best-in-Category Safety Profile

THOMSON REUTERS
·
Oct 03, 2025

Ovid Therapeutics - Regains Compliance With Nasdaq Listing Rule - SEC Filing

THOMSON REUTERS
·
Sep 16, 2025